This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HCV infection.
Upon completion of the program, participants should be able to:
Release Date: May 29, 2020
Expiration Date: May 29, 2021
Estimated time to complete each Module: 30-60 minutes
Media: Web
Paul Kwo, MD
Director of Hepatology
Professor of Medicine
Stanford University School of Medicine
Palo Alto, California
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Stacey Trooskin, MD, PhD
Physician and Director of Viral Hepatitis Program
Jonathan Lax Treatment Center
Philadelphia FIGHT
Philadelphia, Pennsylvania
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Module 1: COVID-19 and HCV Discussion
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2: Epidemiology, Demographics and Current HCV Guidelines
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3: Testing and Diagnosis of Patients with CHC
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4: Linkage to HCV Care and Pre-Treatment Management
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 5: Optimizing HCV Treatment - Simplified Therapy and PWID Management
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Paul Kwo, MD:
|
Mark Sulkowski, MD:
|
Stacey Trooskin, MD:
|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The PIM and ViralEd planners and managers have nothing to disclose.
There are no fees for participating and receiving CME/CE credit for this activity. During the period, May 29, 2020 through May 29, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 15185. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This program requires HTML 5 enabled web browsers such as: Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.
For CME Accreditation Questions, please click HERE
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
